 PLYMOUTH MEETING, Pa., June 9, 2021 PRNewswire -- Harmony Biosciences Holdings, Inc. Harmony Nasdaq: HRMY, a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs, today announced applications for its Patients at the Heart Grant Program open Wednesday, June 9, 2021 for patient-centric organizations working to support and address the challenges of people living with sleep disorders and rare diseases who experience excessive daytime sleepiness EDS. 